CA3123260C — Crystalline hemihydrate of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state form thereof
Assigned to AbbVie Inc · Expires 2025-03-11 · 1y expired
What this patent protects
The present disclosure relates to a crystalline hemihydrate of (3S,4R)-3-ethyl-4-(3Himidazo[l,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N(2,2,2 trifluoroethyl)pyrrolidine-l-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, and processes for preparation …
USPTO Abstract
The present disclosure relates to a crystalline hemihydrate of (3S,4R)-3-ethyl-4-(3Himidazo[l,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N(2,2,2 trifluoroethyl)pyrrolidine-l-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, and processes for preparation of the pharmaceutical compositions.
Drugs covered by this patent
- Rinvoq (upadacitinib) · AbbVie Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.